Welcome to our dedicated page for TELESCOPE INNOVATIONS CP news (Ticker: TELIF), a resource for investors and traders seeking the latest updates and insights on TELESCOPE INNOVATIONS CP stock.
TELESCOPE INNOVATIONS CP (TELIF) is a leading developer of chemical technologies for the pharmaceutical and chemical industries. The company specializes in scalable manufacturing processes and tools, including flexible robotic platforms and artificial intelligence software. With a focus on process innovation, TELIF aims to address challenges in health and sustainability by improving experimental throughput, efficiency, and data quality. Recent achievements include the development of a proprietary recrystallization process for battery recycling feeds and partnerships with industry leaders like METTLER TOLEDO and Shimadzu Scientific Instruments.
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) reported Q1 FY2025 financial results with revenues of $1.2 million, down from $1.5 million in Q1 FY2024. The company recorded an adjusted EBITA loss of $103,177, compared to earnings of $505,171 in the same period last year. Expenses increased to $1.5 million from $1.3 million year-over-year.
Key operational highlights include successful delivery of DirectInject-LC™ products under the Mettler Toledo distribution agreement, with product demonstrations across multiple countries. The company advanced its Self-Driving Labs research with Pfizer, achieving Certified Systems Integrator status for Universal Robots systems. Additionally, Telescope demonstrated production of >99.5% pure lithium carbonate using its ReCRFT™ technology and is building a pilot plant in Vancouver for scale-up studies.
Telescope Innovations (CSE: TELI, OTCQB: TELIF) has announced successful results from its Brine-to-Battery Program, demonstrating the production of battery-grade lithium carbonate (>99% pure) from various North American lithium brines using its proprietary ReCRFT™ technology.
The technology has proven effective with brines from Alberta, Texas, Nevada, and Arkansas, processing materials with original lithium purity ranging from 15% to 93%. Key advantages of ReCRFT™ include elimination of traditional polishing steps in lithium carbonate production from Direct Lithium Extraction (DLE) concentrates, reducing reagent, equipment, energy, and operating costs.
The company has protected the ReCRFT™ technology through a patent application under the Patent Cooperation Treaty and additional jurisdictions, positioning itself to address North America's critical minerals supply challenges.
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) reported financial results for fiscal year 2024, showing revenue growth of 57% to $4.4M from $2.8M in FY2023. The company posted an Adjusted EBITDA loss of $152K, improved from a $225K loss in FY2023. Expenses increased to $5.8M from $3.5M previous year.
Key achievements include launching a multi-year collaboration with Pfizer for self-driving labs development, securing a global distribution agreement with Mettler Toledo for DirectInject-LC™, and obtaining funding for a lithium refinement pilot plant. The company also advanced new IP in lithium sulfide production and battery recycling technologies.
Telescope Innovations (CSE: TELI) (OTCQB: TELIF) has published research demonstrating an AI-driven method to optimize battery-grade lithium carbonate production. The study, conducted with Natural Resources Canada, McMaster University, and the University of Toronto, showcases the company's ReCRFT technology, which achieved over 83% lithium carbonate yields from direct lithium extraction eluates using CO2 as a carbonating reagent. The process specifically addresses challenges in processing North American brines, which contain high impurities and typically require multiple polishing steps.
Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) has achieved Certified Systems Integrator (CSI) status for robotic instruments sold by Universal Robots (UR). This certification enables faster development and deployment of Telescope's Self-Driving Labs (SDLs), which combine advanced process analytical technology, AI, and robotics to accelerate chemistry research.
The CSI status provides Telescope with two key advantages:
- Faster development cycles for SDLs, which aim to optimize chemical synthesis and manufacturing approaches up to 100x faster than traditional methods
- Facilitated deployment of SDLs for clients, including installation, testing, and training with UR robots
This certification strengthens Telescope's position as integrators-of-choice for companies seeking advanced chemical technologies, allowing them to build and deploy more powerful SDLs.
Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) and Altillion Inc. have successfully collaborated to produce battery-quality lithium carbonate from brines. Telescope's proprietary ReCRFT™ recrystallization technology, applied to lithium-containing brines concentrated via Altillion's ALIX process, consistently yielded lithium carbonate exceeding 99.9% purity.
This collaboration aims to establish a secure, sustainable, and on-shore supply of high-purity lithium carbonate for North American battery raw materials. The combined technologies simplify the traditional 5-step lithium brine processing into a more efficient 2-step process, potentially reducing costs and improving energy efficiency. Telescope is now building a lab-scale ReCRFT™ pilot plant in Vancouver, BC, to further advance this goal.
Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) and Standard Lithium (TSXV: SLI) (NYSE American: SLI) have successfully developed a new method for producing high-purity lithium sulfide, a important material for next-generation solid-state batteries (SSBs). The innovative low-temperature, high-purity process addresses key challenges in lithium sulfide production:
- Reduced production costs due to lower energy consumption
- Improved product purity for enhanced SSB performance
- Simplified production process for easier management and scalability
- Environmental benefits from reduced energy use and potentially less hazardous reagents
This breakthrough aims to establish a North American-based resource and infrastructure for next-generation battery materials, potentially transforming the solid-state battery industry.
Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) has signed a master collaborative research agreement with Pfizer Inc. to develop technology aimed at accelerating pharmaceutical R&D through automation, robotics, and artificial intelligence. The multi-year agreement focuses on deploying Self-Driving Laboratories (SDLs), which can optimize material properties and chemical synthesis methods up to 100x faster than traditional research methods.
The collaboration builds on Telescope's previous success in commercializing its DirectInject-LC™ automation product for online chemistry analysis. A joint steering committee will guide the technology development projects, ensuring Telescope's SDL technology is well-positioned for the pharmaceutical industry. This partnership could significantly reduce the time and cost of developing new pharmaceuticals, potentially providing a key competitive advantage in the industry.
Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) has been awarded $400,273 in early-stage funding from the B.C. Centre for Innovation and Clean Energy (CICE) to pilot its proprietary Recrystallization Refinement Technology (ReCRFT™). This technology is a carbon-negative and low-cost method to produce battery-grade lithium carbonate from saltwater brines.
ReCRFT is inspired by pharmaceutical manufacturing approaches and offers advantages such as continuous operation, high process yield, high impurity tolerance, and reduced reagent utilization. It is estimated to reduce lithium refinery plant CapEx by 15-25% and OpEx by 25% compared to incumbent technologies.
The funding will support Telescope's lab-scale pilot, providing key engineering studies and continuous operation demonstrations for potential licensing customers. This project builds on Telescope's previous research efforts with Standard Lithium, Natural Resources Canada, and Canada's Mining Innovation Commercialization Accelerator.
Telescope Innovations, a developer of advanced technologies for the pharmaceutical and chemical industries, announced financial results for Q3 FY 2024. The company reported revenues of CAD $1.2 million for the quarter, with year-to-date revenues exceeding CAD $3.4 million, surpassing the entire fiscal year 2023's revenues. Despite the revenue increase, expenses also rose to CAD $1.42 million for the quarter and CAD $3.94 million year-to-date. However, the company achieved a positive cash flow from operating activities of CAD $40,023 for the year-to-date period. This quarter saw increased sales of the DirectInject-LC product and notable customer engagement through conferences and technology demonstrations.
FAQ
What is the current stock price of TELESCOPE INNOVATIONS CP (TELIF)?
What is the market cap of TELESCOPE INNOVATIONS CP (TELIF)?
What are the core business operations of TELESCOPE INNOVATIONS CP (TELIF)?
What recent achievements has TELESCOPE INNOVATIONS CP (TELIF) made?
What is the focus of TELESCOPE INNOVATIONS CP (TELIF)'s technology?
Who are some of TELESCOPE INNOVATIONS CP (TELIF)'s key partners?
